Unknown

Dataset Information

0

The current status of immunobased therapies for metastatic renal-cell carcinoma.

ABSTRACT: The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

SUBMITTER: Sathianathen NJ 

PROVIDER: S-EPMC5723125 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The current status of immunobased therapies for metastatic renal-cell carcinoma.

Sathianathen Niranjan J NJ   Krishna Suprita S   Anderson J Kyle JK   Weight Christopher J CJ   Gupta Shilpa S   Konety Badrinath R BR   Griffith Thomas S TS  

ImmunoTargets and therapy 20171205

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently av  ...[more]

Similar Datasets

Unknown Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
| S-EPMC5215367 | biostudies-literature
Unknown Metastatic renal cell carcinoma: Current scenario and future trends.
| S-EPMC3876598 | biostudies-other
Unknown Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
| S-EPMC8057358 | biostudies-literature
Unknown Current status of targeted therapy for advanced renal cell carcinoma.
| S-EPMC3332131 | biostudies-literature
Unknown Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
| S-EPMC3868199 | biostudies-other
Unknown Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
| S-EPMC3227914 | biostudies-literature
Unknown The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
| S-EPMC8033221 | biostudies-literature
Unknown Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma.
| S-EPMC6820538 | biostudies-literature
Unknown Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
| S-EPMC8189101 | biostudies-literature
Unknown Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
| S-EPMC3126007 | biostudies-literature